#O-RADS
eu vi pelo x, a nossa queridona de bh que namora um homem trans passou o segundo turno brigando com as outras rads defendendo votar nulo ou dando munição anti-petista
October 26, 2026 at 12:35 PM
SJORANM Community Spotlight: Thank you, Prof. Isabelle Thomassin-Naggara, Hôpital Tenon (AP-HP, Paris)!

O-RADS MRI scores indeterminate adnexal masses 1–5 for malignancy risk (ACR O-RADS guide).

https://www.linkedin.com/feed/update/urn:li:activity:7519780016822530048/

#SJORANM #ORADS
October 24, 2026 at 4:03 PM
How can radiologists avoid diagnostic pitfalls in gynecologic pelvic MRI?

🩻 Standardized MRI protocols improve the assessment of endometriosis, uterine diseases, and adnexal masses.
🎯 O-RADS MRI and FIGO 2023 support structured interpretation, lesion characterization, and staging.
October 19, 2026 at 9:01 AM
o curioso mundo invertido das rads do insta onde o psol é um partido misógino e o pco é um partido feminista
October 17, 2026 at 8:19 PM
Qué hacer cuando un estudio de cáncer de mama llega al celular y dispara falsas alarmas: “Falta una curación científica”
Qué hacer cuando un estudio de cáncer de mama llega al celular y dispara falsas alarmas: “Falta una curación científica”
Una palabra técnica en el informe, las categorías BI-RADS o una imagen que requiere estudios complementarios pueden generar temores en las pacientes. Muchas de esas dudas no se resuelven durante la consulta médica. Infobae consultó a expertos en oncología sobre los elementos que evalúan para interpretar los hallazgos y medir los riesgos
dlvr.it
October 12, 2026 at 5:04 AM
hoje tá sendo uma chuva de transfobia esse site viu - na real desde ontem

o bom é que as rads começaram a sair do esgoto
October 5, 2026 at 12:15 PM
New preprint: with ADAPT-MS, discovery plasma proteomics becomes a diagnostic tool for ovarian cancer. We separate benign from malignant adnexal masses and generalize to 5 validation cohorts. Collaboration with @lengyel-ovca-lab.bsky.social
www.medrxiv.org/content/10.6...
Differentiating benign from malignant adnexal masses by biomarker-agnostic plasma proteomics using adaptive machine learning
Background: Pre-operative triage of adnexal masses with serum CA-125, HE4, and ultrasound (O-RADS) has limited accuracy, contributing to unnecessary surgery. We develop and validate a first of its kind, biomarker panel-free plasma proteomic classifier that distinguishes malignant from benign adnexal masses from a single blood draw, operating directly on discovery-mode mass spectrometry. Methods: In this multicenter prospective observational study, plasma from women with adnexal masses and from healthy controls at a large urban academic center (discovery and four validation cohorts) and an external academic center from another Urban-suburban area (external validation) was analyzed by data-independent-acquisition mass spectrometry (Orbitrap Astral), quantifying >1,000 proteins per sample. Cancerous (malignant, borderline adnexal mass, or metastasis to ovary) versus benign adnexal masses were classified with ADAPT-MS (Adaptive Diagnostic Architecture for Personalized Testing by Mass Spectrometry), which retrains an ElasticNet model for each sample based on the proteins measured. The primary outcome was discrimination (area under the receiver operating characteristic curve [AUC]). Pre-operative O-RADS scores and serum CA-125 were compared and combined with proteomics on matched subsets. Findings: Using a discovery cohort (n=1062), an ADAPT-MS classifier, validated across five independent cohorts (n=623), achieved a summary AUC of 0.835 (cohort range 0.779-0.904). Among patients with pre-operative O-RADS (n=231), proteomics (AUC 0.852) was comparable to O-RADS alone (0.863) and combining them raised discrimination to 0.922. Proteomics outperformed serum CA-125 (0.915 versus 0.777; n=125) and proteome-derived ROMA-like and two-marker surrogates. Biologically, the classification-relevant proteins are enriched for host response proteins rather than tumor cell associated protein changes, comprising ECM remodeling, complement and innate immune response pathways. This explains good detection of tumor with heterogenous pathology and also metastasis to ovary. Interpretation: A single plasma proteomic measurement interpreted using adaptive machine learning discriminates malignant from benign adnexal masses with good internal and external validation, and is complementary to ultrasound, warranting prospective evaluation as a panel-free diagnostic adjunct to imaging. ### Competing Interest Statement MM is an investor in Evosep. All other authors declare no competing interests. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was approved by the Institutional Review Board at The University of Chicago and Roswell Park Cancer Institute, and informed written consent was obtained from all women participating in the study. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors. Max Planck Society for the Advancement of Sciences NIH R35 grant Arthur and Nicole Herbst
www.medrxiv.org
September 28, 2026 at 10:20 AM
O problema maior pra mim é q até onde sei a resposta das transfeministas não a fez repensar e as falas delas caíram muito bem na mão de rads
September 17, 2026 at 5:43 PM
total, mas ela nao se responsabiliza, né. que é o que as rads fazem hoje em dia. elas não batem mais no peito dizendo "sou rad". é aquele discurso conservador com jargões de esquerda, que despertam as tendências microfascistas de pessoas de esquerda, principalmente em torno de sexo e gênero.
September 16, 2026 at 11:57 PM
What is O-RADS? The Ovarian and Adnexal Reporting & Data System helps radiologists characterize ovarian masses. Dr. Myra Feldman explains O-RADS scores & what your report means 👉 https://tinyurl.com/9t8bbknh

#RadiologyInfo #PatientEducation
September 16, 2026 at 7:10 PM
This study compared standard visual assessment of enhancement with semi-quantitative intensity curves (SIC) within O-RADS MRI.
Improving diagnostic performance of O-RADS MRI: semi-quantitative intensity curves vs visual assessment of enhancement - European Radiology
Background O-RADS MRI improves differentiation of benign adnexal lesions managed by a gynecologist and malignant lesions managed by a gynecologic oncologist. Objective To compare O-RADS MRI visual…
buff.ly
September 15, 2026 at 7:01 AM
"These findings highlight how a relatively simple semi-quantitative approach to enhancement may further refine O-RADS MRI risk stratification. 🧠🩻
September 15, 2026 at 7:01 AM
While visual assessment already demonstrated high sensitivity (95%), incorporating SIC significantly improved specificity from 84% to 92% and positive predictive value from 77% to 90%, while maintaining good reproducibility between readers. 📊✨

👉 buff.ly/OrGyaYl (Emmanuel Salinas-Miranda et al.)
Improving diagnostic performance of O-RADS MRI: semi-quantitative intensity curves vs visual assessment of enhancement - European Radiology
Background O-RADS MRI improves differentiation of benign adnexal lesions managed by a gynecologist and malignant lesions managed by a gynecologic oncologist. Objective To compare O-RADS MRI visual…
buff.ly
September 15, 2026 at 7:01 AM
Improving O-RADS MRI: Can Semi-Quantitative Enhancement Analysis Make a Difference? 🎯

Accurate characterization of adnexal masses is essential for appropriate surgical triage.
September 15, 2026 at 7:01 AM
Todo mês tem uma notícia de uma mulher cis negra/não-branca sendo agredida ou impedida de usar o banheiro porque acham que é homem e as rads JURAM que não vão ser afetadas por isso 🤪🤪
É ver o vídeo da comemoração da decisão da suprema corte do reino unido e notar umas rad sapatão mais machudas daquela ilha achando que não serão barradas em banheiro
Todo projeto político baseado na rejeição ao diferente não tem linhas claras e vai acabar da forma alertada pelo Brecht, porque no fundo está a serviço de um grupo mais coeso e delimitado do que os seus seguidores de ocasião.
April 18, 2025 at 7:01 PM
descobri que tem uma desquerida que me chama pelas costas de "imperatriz paulista da não-monogamia" e tô rindo até agora. é o segundo melhor apelido de hater que eu já recebi, o primeiro foram rads me chamando de Butler brasileira
June 15, 2025 at 1:32 AM
As rads estão alinhadas com o PL? Quem diria… (votei)
September 5, 2025 at 9:09 PM
Das rads eu já entendo q fachas mesmo. Sei lá. Mas até q ponto rechaçar o 6x1 n é só a esquerda fisiologista em pacto c as forças produtivas burguesas?
February 14, 2025 at 2:07 AM
Tinha até elas achando de boas Rads terem encontros e apoio de grupos conservadores pois a esquerda não as aceita e as persegue 😭
Além de atrocidades como afirmar que "o movimento queer" quer fazer operação de mudança de sexo em crianças.

Sério, essa porra é um movimento fascista sem tirar nem por
December 18, 2024 at 4:47 PM
This review highlights how MRI, with its superior soft-tissue resolution and multiplanar capabilities, helps:
🔹 Differentiate ovarian vs. non-ovarian lesions
🔹 Classify ovarian cysts using O-RADS MRI
🔹 Integrate T1, T2, DWI, and post-contrast features for accurate diagnosis
ESUR female pelvis group approach to cystic female pelvic lesions - Insights into Imaging
Abstract Cystic female pelvic lesions, whether of ovarian or non-ovarian origin, are prevalent in routine clinical practice, with the majority originating from gynaecological (ovarian) structures,…
link.springer.com
April 10, 2026 at 9:00 AM
📢 MRI-based radiomics model for ovarian mass categorization

In 497 patients, the model (AUC = 0.939) outperformed O-RADS (0.862) and junior radiologists (0.802) and matched senior radiologists (0.886). Particularly effective for O-RADS 4 and cystic-solid masses. (Junjie Jin et al.)
September 2, 2025 at 9:01 AM
This paper examines the advantages and disadvantages of utilising the O-RADS #MRI scoring system in #clinical practice, offering a critical view on the topic. (Stephanie Nougaret et al.)

#InsightsintoImaging #FromTheExperts

insightsimaging.springeropen.com/articles/10....
July 9, 2025 at 12:03 PM